Alice T. Shaw, MD, PhD
Associate Professor of Medicine; Attending Physician
Harvard Medical School; Massachusetts General Hospital
Alice T. Shaw is an associate professor of medicine at Harvard Medical School and an attending physician in the Thoracic Oncology Division at Massachusetts General Hospital. She received her AB in biochemistry from Harvard and her MD and PhD degrees from Harvard Medical School. She did her residency in internal medicine at Massachusetts General Hospital and completed a fellowship in hematology/oncology at Dana-Farber/Massachusetts General Hospital. She completed her postdoctoral work in the laboratory of Dr. Tyler Jacks at MIT.
In addition to caring for patients with lung cancer, Dr. Shaw also performs clinical and translational research. Her research focuses on anaplastic lymphoma kinase (ALK), ROS1 and RET rearrangements in non-small cell lung carcinoma (NSCLC). She was the lead investigator for the global registration studies of crizotinib and ceritinib, which led to regulatory approval of both drugs in advanced ALK-rearranged NSCLC. She was also the lead investigator for crizotinib in ROS1-rearranged NSCLC. Her research focuses on elucidating mechanisms of resistance to targeted therapies, and she is currently leading several clinical trials and translational efforts aimed at overcoming drug resistance.